Announced Mon, 17 Aug · 13:01 IST
Gland Pharma Q1 FY27 earnings call transcript filed
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹2965.20
prior close
₹2905.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0-0.3-1.1-3.7-4.3-4.0-5.2——————
Up moveDown movePending
AI summary
Gland Pharma filed Q1 FY27 earnings call transcript. Revenue grew 20% YoY to INR18,003 million; adjusted EBITDA INR5,102 million at 28% margins; PAT up 47% YoY to INR3,170 million. US revenues grew 32%. Announced USD 90-100 million manufacturing deal with a global pharma major, plus collaborations for liposomal products and depot APIs. R&D up 16% YoY.
Likely market impact
Strong quarter with 20% revenue and 47% PAT growth. Large CDMO deal adds revenue visibility from CY 2029. Margin trajectory supported by utilization.